Drug resistance genes and trailing growth in Candida albicans isolates

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 2, 2004, Pages 217-224

  Lee, Mi Kyung ^a,b   Williams, Laura E ^a   Warnock, David W ^a   Arthington Skaggs, Beth A ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b Chung Ang University College of Medicine   (South Korea)

Author keywords

Azole drug resistance; C. albicans; Molecular mechanisms

Indexed keywords

CARRIER PROTEIN; FLUCONAZOLE; FUNGAL DNA; ITRACONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN CDR1; PYRROLE DERIVATIVE; SQUALENE MONOOXYGENASE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA ALBICANS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SEQUENCE; DRUG EXPOSURE; DRUG RESPONSE; FUNGUS GROWTH; FUNGUS ISOLATION; GENE CONTROL; GENETIC SCREENING; HOMOZYGOSITY; HUMAN; IN VITRO STUDY; MOLECULAR GENETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CANDIDIASIS; DNA, COMPLEMENTARY; DNA, FUNGAL; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; GENES, FUNGAL; GENES, MDR; HUMANS; MICROBIAL SENSITIVITY TESTS; POINT MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEROLS; TRANSCRIPTION, GENETIC;

EID: 1242352902     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh040     Document Type: Article

References (32)

1. Arthington-Skaggs, B. A., Lee-Yang, W., Ciblak, M. A. et al. (2002). Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantification method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrobial Agents and Chemotherapy 46, 2477-81.
2. Rex, J. H., Nelson, P. W., Paetznick, V. L. et al. (1998). Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrobial Agents and Chemotherapy 42, 129-34.
3. Arthington-Skaggs, B. A., Warnock, D. W. & Morrison, C. J. (2000). Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrobial Agents and Chemotherapy 44, 2081-5.
4. Revankar, S. G., Kirkpatrick, W. R., McAtee, R. K. et al. (1998). Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. Journal of Clinical Microbiology 36, 153-6.
5. Smith, W. L. & Edlind, T. D. (2002). Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation. Antimicrobial Agents and Chemotherapy 46, 3532-9.
6. Sanglard, D. & Odds, F. C. (2002). Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infectious Diseases 2, 73-85.
7. White, T. C. (1997). Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrobial Agents and Chemotherapy 41, 1482-7.
8. Lasker, B. A., Elie, C. M., Lott, T. J. et al. (2001). Molecular epidemiology of Candida albicans strains isolated from the oropharynx of HIV-positive patients at successive clinic visits. Medical Mycology 39, 341-52.
9. Sobel, J. D., Ohmit, S. E., Schuman, P. et al. (2001). The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. Journal of Infectious Diseases 183, 286-93.
10. National Committee for Clinical Laboratory Standards. (1997). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A. NCCLS, Villanova, PA, USA.
11. Lai, M. H. & Kirsch, D. R. (1989). Nucleotide sequence of cytochrome P450 L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans. Nucleic Acids Research 17, 804.
12. Frade, J. P., Lee-Yang, W., Freitas, G. B. et al. (2002). Quantification of drug efflux gene expression in Candida albicans and Candida glabrata using the LightCycler Real-Time RT-PCR. In Programs and Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract M-224, p. 379. American Society for Microbiology, Washington, DC, USA.
13. White, T. C. (1997). The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14α demethylase in Candida albicans. Antimicrobial Agents and Chemotherapy 41, 1488-94.
14. Favre, B., Didmom, M. & Ryder, N. S. (1999). Multiple amino acid substitutions in lanosterol 14α-demethylase contribute to azole resistance in Candida albicans. Microbiology 145, 2715-25.
15. Asai, K., Tsuchimori, N., Okonogi, K. et al. (1999). Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P-450. Antimicrobial Agents and Chemotherapy 43, 1163-9.
16. White, T. C., Holleman, S., Dy, F. et al. (2002). Resistance mechanisms in clinical isolates of Candida albicans. Antimicrobial Agents and Chemotherapy 46, 1704-13.
17. Perea, S., López-Ribot, J. L., Kirkpatrick, W. R. et al. (2001). Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy 45, 2676-84.
18. Franz, R., Kelly, S. L., Lamb, D. C. et al. (1998). Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrobial Agents and Chemotherapy 42, 3065-72.
19. Kakeya, H., Miyazaki, Y., Miyazaki, H. et al. (2000). Genetic analysis of azole resistance in the Darlington strain of Candida albicans. Antimicrobial Agents and Chemotherapy 44, 2985-90.
20. Lamb, D. C., Kelly, D. E., Schunck, W. H. et al. (1997). The mutation T315A in the Candida albicans sterol 14α-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. Journal of Biological Chemistry 272, 5682-8.
21. Löffler, J., Kelly, S. L., Hebart, H. et al. (1997). Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiology Letters 151, 263-8.
22. Marichal, P., Koymans, L., Willemsens, S. et al. (1999). Contribution of mutations in the cytochrome P450 14α-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145, 2701-13.
23. Martínez, M., López-Ribot, J. L., Kirkpatrick, W. R. et al. (2002). Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. Journal of Antimicrobial Chemotherapy 49, 515-24.
24. Sanglard, D., Ischer, F., Koymans, L. et al. (1998). Amino acid substitutions in the cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrobial Agents and Chemotherapy 42, 241-53.
25. Pujol, C., Reynes, J., Renaud, F. et al. (1993). The yeast Candida albicans has a clonal mode of reproduction in a population of infected human immunodeficiency virus-positive patients. Proceedings of the National Academy of Sciences, USA 90, 9456-9.
26. Tibayrenc, M., Kjellberg, F., Arnaud, J. et al (1991). Are eukaryotic microorganisms clonal or sexual? A population genetics vantage. Proceedings of the National Academy of Sciences, USA 88, 5129-33.
27. Marr, K. A., Lyons, C. N., Rustad, T. et al. (1998). Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrobial Agents and Chemotherapy 42, 2584-9.
28. Albertson, G. D., Niimi, M., Cannon, R. D. et al. (1996). Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrobial Agents and Chemotherapy 40, 2835-41.
29. Lopez-Ribot, J. L., McAtee, R. K., Lee, L. N. et al. (1998). Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrobial Agents and Chemotherapy 42, 2932-7.
30. Lyons, C. N. & White, T. C. (2000). Transcriptional analyses of antifungal drug resistance in Candida albicans. Antimicrobial Agents and Chemotherapy 44, 2296-2303.
31. Henry, K. W., Nickels, J. T. & Edlind, T. D. (2000). Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrobial Agents and Chemotherapy 44, 2693-2700.
32. Graybill, J. R., Montalbo, E., Kirkpatrick, W. R. et al. (1998) Fluconazole versus Candida albicans: a complex relationship. Antimicrobial Agents and Chemotherapy 42, 2938-42.